Lexaria Bioscience Corp.

Listed Company

LEXXCIK 0001348362NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Aug 31

Period

FY 2025

Revenue

$705.9K

Net Income

$-11.90M

Total Assets

$4.18M

Equity

$2.99M

Shares Out

24.79M

Op. Cash Flow

$-10.45M

Business

Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented drug delivery technology that enhances oral bioavailability and tolerability of active pharmaceutical ingredients. The company formulates DehydraTECH with long-chain fatty acid-rich triglyceride oils and carriers for APIs including GLP-1/GIP drugs, cannabinoids (CBD), nicotine, vitamins, pain medications, antivirals and hormones for pharmaceutical, nutraceutical, over-the-counter and consumer product use. Key business components include proprietary IP management through subsidiaries, licensing of DehydraTECH across molecule-specific subsidiaries, and R&D and clinical development programs. Lexaria pursues global patent protection and distributes technology via licenses, partnerships and product-format integrations across pharmaceutical, nutraceutical, food and beverage channels.

Summary from filing dated 2025-11-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Revenue	705,923	464,278	226,208	255,397	722,738
Cost of goods sold	2,720	4,822	31,500	71,841	175,346
Gross profit	703,203	459,456	194,708	183,556	547,392
Research and development	8	2	4	2	1
General and administrative	4	4	3	5	5
Total operating expenses	13	6	7	7	6
Loss from operations	−12	−6	−7	−7	−6
Interest income	3,017	14,311	—	—	—
Unrealized loss on marketable securities	−33,714	−69,835	—	—	—
Total other income (loss)	−30,697	−55,524	—	—	—
Net loss	−12	−6	−7	−7	—
Less: Net loss attributable to non-controlling interest	−9,593	−13,309	−47,626	−114,329	−159,142
Net loss attributable to Lexaria shareholders	−12	−6	−7	−7	−4
Foreign currency translation adjustment	−50,519	−19,816	—	—	—
Total comprehensive loss	−12	−6	−7	—	—
Basic and diluted loss per share	−0.66	−0.47	−1.01	—	—
- Basic and diluted	18	12	7	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Cash	2	6	1	6	11
Short-term investments	143,267	0	—	—	—
Marketable securities	22,093	55,807	125,642	347,335	833,841
Accounts receivable	368,358	154,477	126,686	201,784	342,401
Prepaid expenses and other current assets	1	1	546,783	—	—
Total Current Assets	3	8	2	7	12
Long-term receivables	64,013	63,575	48,559	—	—
Right of use assets	106,816	134,843	167,446	52,444	91,041
Intellectual property, net	307,818	516,676	—	—	—
Property & equipment, net	228,129	254,709	254,143	315,505	368,213
Total Non-current Assets	706,776	969,803	932,773	856,411	823,877
TOTAL ASSETS	4	9	3	8	13
Accounts payable and accrued liabilities	1	1	239,941	151,449	105,496
Deferred revenue	0	4,963	—	—	—
Lease liability, current	30,417	28,047	—	—	—
Total Current Liabilities	1	1	267,735	194,036	153,276
Lease liabilities - non-current	78,903	109,319	—	—	—
TOTAL LIABILITIES	2	1	403,908	201,437	203,265
Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding: 19,559,179 and 15,810,205 at August 31, 2025 and August 31, 2024, respectively	19,559	15,810	8,091	5,951	5,727
Additional paid-in capital	67	60	49	47	45
Accumulated Deficit	−63	−52	−46	−39	−32
Accumulated other comprehensive loss	−70,335	−19,816	0	—	—
Equity attributable to shareholders of Lexaria	3	8	3	8	13
Non-controlling Interest	−386,942	−377,349	—	—	—
Total Stockholders' Equity	3	8	3	8	13
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	4	9	3	8	13

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31
Net loss	−12	−6	−7	—	—
Stock based compensation	859,494	492,236	170,382	752,591	410,007
Depreciation and amortization	87,825	76,153	145,397	102,718	111,718
Impairment loss	247,364	57,836	—	—	—
Bad debt expense	0	7,760	—	0	50,500
Noncash lease expense	28,027	32,603	—	—	—
Lease accretion	9,047	6,672	—	—	—
Accounts receivable	−213,881	−35,551	26,539	−137,491	189,580
Prepaid expenses and deposits	55,313	−641,034	—	—	—
Long-term receivables	−438	−15,016	—	—	—
Accounts payable and accrued liabilities	396,637	826,468	88,492	50,726	13,803
Operating lease liability	−37,093	−33,273	−44,814	0	—
Deferred revenue	−4,962	4,962	0	0	−44,255
Net cash used in operating activities	−10	−5	−6	−5	−4
Short-term investments	−143,267	0	—	—	—
Additions to intellectual property	−75,106	−145,591	−135,862	−131,448	−79,493
Purchase of equipment	−24,646	−43,014	−33,748	−49,192	—
Net cash used in investing activities	−243,019	−188,605	−169,610	−180,640	193,880
Proceeds from exercise of stock options	0	2,875	—	—	—
Proceeds from shares sold for cash	6	4	—	—	—
Proceeds from exercise of warrants	0	6	—	0	4
Net cash provided by financing activities	6	10	2	−44,600	13
Effect of exchange rate changes on cash	−50,519	−19,816	—	—	—
Net change in cash for the period	−5	5	−4	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro